2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged._老虎社区_美港股上老虎

2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.

Barrons2021-12-17

The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price. Immix (ticker: IMMX) is the third company this week to trade below its ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

ppyy
·2021-12-17
Ok
回复
3
举报
收起
- Ddsl:
  Ok
  2021-12-17
  回复
  举报
- ppyy:
  ok
  2021-12-17
  回复
  举报
HLPA
·2021-12-17
Both will plunge deeper
回复
2
举报
收起
- jaswsf:
  Ok
  2021-12-17
  回复
  举报
javiery
·2021-12-17
Like
回复
5
举报
收起
- Alexlee81:
  thanks
  2021-12-17
  回复
  举报
- LEEQF:
  Commented
  2021-12-17
  回复
  举报
OddEyeCircle
·2021-12-17
Please let me know if
回复
3
举报
Naqman
·2021-12-17
Like and comment please
回复
4
举报
收起
- javiery:
  ok
  2021-12-17
  回复
  举报
- OddEyeCircle:
  please let me know
  2021-12-17
  回复
  举报
JY_02222
·2021-12-17
Nice
回复
4
举报
SmilingDevil
·2021-12-17
Like
回复
5
举报
收起
- JY_02222:
  Done
  2021-12-17
  回复
  举报
Eddieash
·2021-12-17
Like please , ty
回复
6
举报
收起
- Naqman:
  liked
  2021-12-17
  回复
  举报
GoG
·2021-12-17
K
回复
4
举报
收起
- GoG:
  k
  2021-12-17
  回复
  举报
newcomer676
·2021-12-17
like
回复
4
举报
收起
- Vonz:
  ok
  2021-12-17
  回复
  举报
yl2021
·2021-12-17
Like
回复
2
举报
收起
- newcomer676:
  ok
  2021-12-17
  回复
  举报
kevinlaisq
·2021-12-17
Pls like
回复
3
举报
收起
- yl2021:
  ok
  2021-12-17
  回复
  举报
牛劲十足
·2021-12-17
Like
回复
3
举报
JeremyEe
·2021-12-17
Hi
回复
4
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1131183374?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-17 15:00","share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","id":"1131183374","market":"us","top_or_hot":-1,"title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","media":"Barrons","content":"<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">网页链接</a>\n\n</div>\n","source":"market_watch","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMMX","symbol_name":"Immix Biopharma, Inc","start_time":0,"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","article_id":"1131183374","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","pubTimestamp":1639724439,"sourceInfo":{"source_id":"market_watch","name":"华尔街大事件"},"weMediaInfo":null,"summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","collect":0,"end_time":0,"defaultTopTitle":"marketwatch.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"translate_title":"两家生物技术公司周四开始交易。一个跳，另一个跳。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNOX":0.9,"IMMX":0.9},"content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":699053757,"gmtCreate":1639726907459,"gmtModify":1639726907719,"author":{"id":"3553039767902975","authorId":"3553039767902975","name":"ppyy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699053757","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7021087,"gmtCreate":1639727947669,"gmtModify":1639727947700,"authorId":3572567683672897,"author":{"id":3572567683672897,"authorId":3572567683672897,"name":"Ddsl","avatar":"https://static.tigerbbs.com/4349a7a2362135d26685a45e48253c3d","vip":1,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699053757,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":7020945,"gmtCreate":1639726912651,"gmtModify":1639726912756,"authorId":3553039767902975,"author":{"id":3553039767902975,"authorId":3553039767902975,"name":"ppyy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699053757,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":699053003,"gmtCreate":1639726733824,"gmtModify":1639726734574,"author":{"id":"3569274903458035","authorId":"3569274903458035","name":"HLPA","avatar":"https://static.tigerbbs.com/07e7b987a9127c5a47dbc3ae02db548b","vip":1,"crmLevel":8,"crmLevelSwitch":0},"htmlText":"Both will plunge deeper","listText":"Both will plunge deeper","text":"Both will plunge deeper","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699053003","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7020948,"gmtCreate":1639726965033,"gmtModify":1639726965070,"authorId":3571893886885807,"author":{"id":3571893886885807,"authorId":3571893886885807,"name":"jaswsf","avatar":"https://static.tigerbbs.com/ed600b3aaba5cb409e893412ae0ee2a9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699053003,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"CN"},{"id":699024411,"gmtCreate":1639726282828,"gmtModify":1639726282974,"author":{"id":"3578269878229068","authorId":"3578269878229068","name":"javiery","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699024411","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7022111,"gmtCreate":1639736115449,"gmtModify":1639736115548,"authorId":4098656676523110,"author":{"id":4098656676523110,"authorId":4098656676523110,"name":"Alexlee81","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699024411,"type":1,"supId":7020911,"prevId":0,"content":"<u>thanks</u>","text":"<u>thanks</u>","html":"<u>thanks</u>"},{"id":7020911,"gmtCreate":1639726360695,"gmtModify":1639726360728,"authorId":3572235673675008,"author":{"id":3572235673675008,"authorId":3572235673675008,"name":"LEEQF","avatar":"https://static.tigerbbs.com/ead66a2c538631d15658309f808c7d40","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699024411,"type":1,"supId":0,"prevId":0,"content":"Commented","text":"Commented","html":"Commented"}],"langContent":"CN"},{"id":699022049,"gmtCreate":1639725945378,"gmtModify":1639725945737,"author":{"id":"3582065904370135","authorId":"3582065904370135","name":"OddEyeCircle","avatar":"https://static.tigerbbs.com/bd89742cea79ac97ec7da1a7bdbc2a14","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Please let me know if","listText":"Please let me know if","text":"Please let me know if","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699022049","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":699026463,"gmtCreate":1639725917992,"gmtModify":1639725918205,"author":{"id":"3568009000536078","authorId":"3568009000536078","name":"Naqman","avatar":"https://static.tigerbbs.com/fdf2c1b210def3e667e2054939598585","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like and comment please","listText":"Like and comment please","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699026463","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7020896,"gmtCreate":1639726277906,"gmtModify":1639726278018,"authorId":3578269878229068,"author":{"id":3578269878229068,"authorId":3578269878229068,"name":"javiery","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699026463,"type":1,"supId":7020841,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":7020841,"gmtCreate":1639725950276,"gmtModify":1639725950313,"authorId":3582065904370135,"author":{"id":3582065904370135,"authorId":3582065904370135,"name":"OddEyeCircle","avatar":"https://static.tigerbbs.com/bd89742cea79ac97ec7da1a7bdbc2a14","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699026463,"type":1,"supId":0,"prevId":0,"content":"please let me know","text":"please let me know","html":"please let me know"}],"langContent":"CN"},{"id":699026879,"gmtCreate":1639725859094,"gmtModify":1639725859398,"author":{"id":"3581989267840978","authorId":"3581989267840978","name":"JY_02222","avatar":"https://static.tigerbbs.com/56c9cab1743301942105239814a6ac4a","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699026879","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":699026192,"gmtCreate":1639725854306,"gmtModify":1639725854385,"author":{"id":"4099621945860130","authorId":"4099621945860130","name":"SmilingDevil","avatar":"https://static.tigerbbs.com/5eaaba5421ec75b5d747f02a5980586a","vip":1,"crmLevel":7,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699026192","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7020830,"gmtCreate":1639725864275,"gmtModify":1639725864308,"authorId":3581989267840978,"author":{"id":3581989267840978,"authorId":3581989267840978,"name":"JY_02222","avatar":"https://static.tigerbbs.com/56c9cab1743301942105239814a6ac4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699026192,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"CN"},{"id":699026904,"gmtCreate":1639725778058,"gmtModify":1639725788116,"author":{"id":"3581678169581963","authorId":"3581678169581963","name":"Eddieash","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Like please , ty","listText":"Like please , ty","text":"Like please , ty","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699026904","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7020835,"gmtCreate":1639725907193,"gmtModify":1639725907227,"authorId":3568009000536078,"author":{"id":3568009000536078,"authorId":3568009000536078,"name":"Naqman","avatar":"https://static.tigerbbs.com/fdf2c1b210def3e667e2054939598585","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699026904,"type":1,"supId":0,"prevId":0,"content":"liked","text":"liked","html":"liked"}],"langContent":"CN"},{"id":699021907,"gmtCreate":1639725460105,"gmtModify":1639725460473,"author":{"id":"3570186020309805","authorId":"3570186020309805","name":"GoG","avatar":"https://static.tigerbbs.com/1c9fbe31d027bcf439a17955df60352f","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699021907","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7020792,"gmtCreate":1639725464987,"gmtModify":1639725465018,"authorId":3570186020309805,"author":{"id":3570186020309805,"authorId":3570186020309805,"name":"GoG","avatar":"https://static.tigerbbs.com/1c9fbe31d027bcf439a17955df60352f","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699021907,"type":1,"supId":0,"prevId":0,"content":"k","text":"k","html":"k"}],"langContent":"CN"},{"id":699023724,"gmtCreate":1639725404735,"gmtModify":1639725404995,"author":{"id":"3582720098998598","authorId":"3582720098998598","name":"newcomer676","avatar":"https://static.tigerbbs.com/915835840baa58cd8ff045fc189b3a3f","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699023724","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7020791,"gmtCreate":1639725462082,"gmtModify":1639725462114,"authorId":3581046107767827,"author":{"id":3581046107767827,"authorId":3581046107767827,"name":"Vonz","avatar":"https://static.tigerbbs.com/5a1cb72de358038a377e7053d898bb82","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699023724,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":699023252,"gmtCreate":1639725373627,"gmtModify":1639725374716,"author":{"id":"3576231438371359","authorId":"3576231438371359","name":"yl2021","avatar":"https://static.tigerbbs.com/9130003d93212acf586123bc8fe8a1e0","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699023252","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7020786,"gmtCreate":1639725410918,"gmtModify":1639725411012,"authorId":3582720098998598,"author":{"id":3582720098998598,"authorId":3582720098998598,"name":"newcomer676","avatar":"https://static.tigerbbs.com/915835840baa58cd8ff045fc189b3a3f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699023252,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":699029409,"gmtCreate":1639725280642,"gmtModify":1639725281194,"author":{"id":"3572874548548490","authorId":"3572874548548490","name":"kevinlaisq","avatar":"https://static.tigerbbs.com/329de1199f764a89b7cadf50308e183d","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699029409","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7020781,"gmtCreate":1639725368251,"gmtModify":1639725368354,"authorId":3576231438371359,"author":{"id":3576231438371359,"authorId":3576231438371359,"name":"yl2021","avatar":"https://static.tigerbbs.com/9130003d93212acf586123bc8fe8a1e0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699029409,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"CN"},{"id":699029263,"gmtCreate":1639725268554,"gmtModify":1639725269161,"author":{"id":"3568026014768326","authorId":"3568026014768326","name":"牛劲十足","avatar":"https://static.tigerbbs.com/8fbaf4c859c3c0e4072e34bf8ae302ba","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699029263","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":699065256,"gmtCreate":1639724687828,"gmtModify":1639724688082,"author":{"id":"3578016956086861","authorId":"3578016956086861","name":"JeremyEe","avatar":"https://static.tigerbbs.com/e4251e60b7916b8816ebb7a4c9bd615c","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699065256","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":34,"commentSize":14,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}